PhaseBio Pharmaceuticals, Inc.
http://www.phasebio.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From PhaseBio Pharmaceuticals, Inc.
PhaseBio’s Bentracimab Could Benefit From Growth In Brilinta Demand
The antiplatelet drug-reversal agent could see uptake grow in tandem with that of Brilinta, but there is a history of drugs in similar indications underperforming on the market.
Deal Watch: Roche Terminates Gene Therapy Alliance, Partners In IBD With Synlogic
Roche gives back choroideremia candidate to 4D Molecular after reviewing Phase I data, partners on synthetic GI therapy with Synlogic. AbbVie opts to acquire TeneoOne under 2019 agreement.
Abingworth Offers Home For Big Pharma Pipeline Projects
The UK-headquartered life sciences investment firm has comfortably exceeded its target of $350m for a fund dedicated to taking on late-stage products, incurring all the clinical and regulatory risk and receiving a pre-negotiated return once the drug is approved.
Scrip Asks…What Does 2021 Hold For Biopharma? Part 3: Patient Access To Health Care
Executives share their expectations and hopes around the multi-faceted topic of patient access to medicines. From health inequities to value assessment and reimbursement trends, expectations for change abound.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
-
Biotechnology
- Large Molecule
- Synthesis Technologies, Production Processes